OFATUMUMAB WITH IVAC FOR DLBCL PATIENTS WHO FAILED R‐CHOP AND WERE NOT CANDIDATES FOR HIGH‐DOSE THERAPY AND ASCT ‐ PHASE 2 TRIAL OF THE POLISH LYMPHOMA RESEARCH GROUP (PLRG‐8). (12th June 2019) - Paszkiewicz‐Kozik, E.